Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Apr 30;33(6):E94–E98. doi: 10.1002/clc.20621

Safety of Selective Serotonin Reuptake Inhibitor Use Prior to Coronary Artery Bypass Grafting

Glen L Xiong 2,✉, Wei Jiang 1,2, Robert M Clare 3, Linda K Shaw 3, Peter K Smith 3,4, Christopher M O'Connor 1,3,5, K Ranga 1, R Krishnan 2, L Kristin Newby 1,3,5
PMCID: PMC6653610  PMID: 20552618

Abstract

Background

Selective serotonin reuptake inhibitors (SSRIs) have been shown to increase bleeding risks. This study examined the association of perioperative coronary artery bypass grafting (CABG) bleeding risks and SSRI use prior to CABG.

Hypothesis

SSRI may be associated with increased bleeding risks after CABG resulting in elevated reoperation rates due to bleeding complications.

Methods

Patients who underwent CABG between 1999 and 2003 (n = 4794) were identified in a tertiary medical center. SSRI use (n = 246) was determined using inpatient pharmacy records. Outcomes included primary end point of reoperation due to bleeding complications and other secondary measures. Multivariate regression models were constructed to adjust for baseline differences between SSRI and control groups.

Results

Reoperation due to bleeding complications among SSRI users was not significantly different (odds ratio [OR]: 1.14 (0.52–2.47); P = 0.75) compared to the control group. Other secondary outcomes and 30‐day mortality (2.0% in SSRI vs 2.1% in control group; P = 0.92) between the 2 groups were similar. However, the adjusted total volume of postoperative red blood cell (RBC) units transfused was higher in the SSRI group.

Conclusion

We conclude that there is no compelling evidence to limit the use of SSRIs among patients with coronary artery disease who undergo CABG given the current evidence. Further research may be needed on individual SSRI medications. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (107.1 KB).

References

  • 1. Blumenthal JA, Lett HS, Babyak MA, et al; NORG Investigators. Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet 2003; 362: 604–609. [DOI] [PubMed] [Google Scholar]
  • 2. Pignay‐Demaria V, Lesperance F, Demaria RG, et al. Depression and anxiety and outcomes of coronary artery bypass surgery. Ann Thorac Surg 2003; 75: 314–321. [DOI] [PubMed] [Google Scholar]
  • 3. Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007; 120: 525–530. [DOI] [PubMed] [Google Scholar]
  • 4. Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin reuptake inhibitors prior to coronary artery bypass grafting. Am J Cardiol 2006; 98(1): 42–47. [DOI] [PubMed] [Google Scholar]
  • 5. Cooper TA, Valcour VG, Gibbons RB, et al. Spontaneous ecchymoses due to paroxetine administration. Am J Med 1998; 104: 197–198. [DOI] [PubMed] [Google Scholar]
  • 6. Serebruany VL, Glassman AH, Malinin AI; SADHART Study Group . Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events. Circulation 2003; 108: 939–944. [DOI] [PubMed] [Google Scholar]
  • 7. Serebruany VL, Suckow RF, Cooper TB, et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N‐desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry 2005; 162: 1165–1170. [DOI] [PubMed] [Google Scholar]
  • 8. De Abajo FJ, Rodriguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case‐control study. BMJ 1999; 319: 1106–1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Dalton SO, Johanse C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. Arch Intern Med 2003; 163: 59–64. [DOI] [PubMed] [Google Scholar]
  • 10. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch.Intern.Med 2004; 164: 2367–2370. [DOI] [PubMed] [Google Scholar]
  • 11. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323: 655–658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006; 119: 113–116. [DOI] [PubMed] [Google Scholar]
  • 13. Dent LA, Orrock MW. Warfarin‐fluoxetine and diazepam‐fluoxetine interaction. Pharmacotherapy 1997; 17: 170–172. [PubMed] [Google Scholar]
  • 14. De Maistre E, Allart C, Lecompte T, et al. Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors. Am J Med 2002; 113: 530–532. [DOI] [PubMed] [Google Scholar]
  • 15. Movig K, Janssen M, Malefijt J, et al. Relationship of serotonergic antidepressants and need for bleed transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163: 2354–2358. [DOI] [PubMed] [Google Scholar]
  • 16. Andreasen JJ, Riis A, Hjortdal VE, et al. Effect of selective serotonin reuptade inhibitors on requirement for allogeneic red blood cell transfussion following coronary artery bypass surgery. Am J Cardiovasc Drugs 2006; 6(4): 243–250. [DOI] [PubMed] [Google Scholar]
  • 17. Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment. A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2008; 118: 1768–1775. [DOI] [PubMed] [Google Scholar]
  • 18. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 2008; 300(18): 2161–2171. [DOI] [PubMed] [Google Scholar]
  • 19. Harris PJ, Harrel FE, Lee KL, Behar VS, Rosati RA. Survival in medically treated coronary artery disease. Circulation 1979; 60: 1259–1269. [DOI] [PubMed] [Google Scholar]
  • 20. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249–258. [DOI] [PubMed] [Google Scholar]
  • 21. Kim J H‐J, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008; 156(5): 886–892. [DOI] [PubMed] [Google Scholar]
  • 22. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757–763. [DOI] [PubMed] [Google Scholar]
  • 23. Salkeld E, Ferris LE, Juurlink DN. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 2008; 28(2): 230–234. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES